ErinEKershawMD

Summary

• My academic mission is to forward the understanding and treatment of obesity and related metabolic disorders by combining basic and translational research with clinical expertise. Obesity is a global public health threat that is frequently associated with additional metabolic abnormalities including insulin resistance, glucose intolerance, dyslipidemia, and hypertension (the metabolic syndrome). Together these abnormalities contribute to diseases affecting virtually every organ system. My laboratory focuses on defining the mechanisms by which “fat” contributes to normal metabolism and disease. Most recently, these efforts have focused on understanding 1) intracellular lipid homeostasis and pathways of triacylglycerol hydrolysis (lipolysis), 2) novel adipocyte-secreted factors and their relationship to metabolic disease, and 3) novel genes/loci linked to metabolic diseases in humans. To achieve our goals, we use a combination of molecular, cellular, physiological, translational, epidemiological, and interventional approaches. Our ultimate goal is to develop more effective strategies for prevention and treatment of obesity and its complications. In addition to the above translational research program, I also contribute to industry-sponsored clinical trials related to rare lipid and adipose tissue disorders, particularly those that contribute to severe hypertriglyceridemia and insulin resistance. Most recently these efforts have included studies related to severe hypertriglyceridemia +/- pancreatitis and incretin-therapies for obesity and its complications. Our ultimate goal is to develop more effective strategies for prevention and treatment of severe hypertriglyceridemia and adipose tissue disorders.